Skip to main content

Clinical Trials Using Anti-LAG-3 Monoclonal Antibody

Review the clinical trials studying anti-lag-3 monoclonal antibody on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 26-44 of 44

Cemiplimab and Fianlimab before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer, N-PLANC Trial
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Nivolumab in Combination with Relatlimab in Treating Patients with Active Melanoma Brain Metastases
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Combined Immunotherapy with Ipilimumab and Nivolumab or Nivolumab and Relatlimab and Radiation Therapy before Surgery for the Treatment of Sinonasal and Anorectal Melanoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Relatlimab, Nivolumab, and Ipilimumab for the Treatment of Unresectable or Metastatic Melanoma with Asymptomatic or Symptomatic Brain Metastases
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Immunotherapy in Combination with Radiation Therapy, with or without Platinum Doublet Chemotherapy, for the Treatment of Patients with Stage II or III Locally Advanced and Unresectable Non-Small Cell Lung Cancer, TRIPL Trial
Status: Active
Location: Montefiore Medical Center-Weiler Hospital, Bronx, New York
Nivolumab Alone or in Combination with Relatlimab or Ipilimumab for the Treatment of Resectable Stage III-IVA Head and Neck Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Nivolumab with or without Ipilimumab or Relatlimab in Treating Patients with Unresectable, Metastatic, or Refractory Basal Cell Carcinoma
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Neoadjuvant Opdualag versus Nivolumab for the Treatment of Resectable High-Risk Basal Cell Carcinoma
Status: Active
Location: UC San Diego Moores Cancer Center, La Jolla, California
Nivolumab with or without Relatlimab given Prior to Surgery and Temozolomide and Radiation Therapy for the Treatment of IDH Wildtype Newly Diagnosed Glioblastoma
Status: Active
Location: Duke University Medical Center, Durham, North Carolina
Cemiplimab with or without Fianlimab for the Treatment of Older Patients with Localized or Locally Advanced MSI-H Colorectal Cancer
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Neoadjuvant Anti-PD-L1 Immunotherapy for the Treatment of Advanced Melanoma
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Ipilimumab in Combination with Relatlimab and Nivolumab for the First Line Therapy in Patients with Stage III-IV Unresectable or Metastatic Melanoma, TRINITY Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
A Clinical Trial Evaluating the Safety and Preliminary Effectiveness of HEPZATO with Immunotherapy in Patients with Metastatic Melanoma and Liver Metastasis
Status: Active
Location: University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin
Intralesional Influenza Vaccine for the Treatment of Stage I-III and IV Melanoma
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Memory-Like Natural Killer Cell Therapy with Interlekin-2, Nivolumab, and Relatlimab for the Treatment of Patients with Advanced or Metastatic Melanoma after Progression on Checkpoint Inhibitors
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
Status: Active
Location: See ClinicalTrials.gov
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
Status: Enrolling by Invitation
Location: See ClinicalTrials.gov
Cemiplimab or Cemiplimab plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma
Status: Temporarily Closed to Accrual
Location: 3 locations